Abstract:Loss-of-function mutations in methyl-CpG binding protein 2 (MECP2) cause Rett syndrome, a postnatal neurodevelopmental disorder that occurs in ~1/10,000 live female births. MeCP2 binds to methylated cytosines across genomic DNA and recruits various partners to regulate gene expression. MeCP2 has been shown to repress transcription in vitro and interacts with co-repressors such as the Sin3A and NCoR complexes. Based on these observations, MeCP2 has been largely considered as a repressor of transcription. However, a mouse model of RTT displays many down-regulated genes, and those same genes are up-regulated in a MECP2 duplication mouse model. Furthermore, TCF20, which has been associated with transcriptional activation, have recently been identified as a protein interactor of MeCP2. These data broaden the potential functions of MeCP2 as a regulator of gene expression. Yet, the molecular mechanisms underlying MeCP2-dependent gene regulation remain largely unknown. Here, using a human MECP2 gain-of-function Drosophila model, we screened for genetic modifiers of MECP2-induced phenotypes. Our approach identified several subunits of the Drosophila super elongation complex, a P-TEFb containing RNA polymerase II (RNA pol II) elongation factor required for the release of promoter-proximally paused RNA pol II, as genetic interactors of MECP2. We discovered that MeCP2 physically interacts with the SEC in human cells and in the mouse brain. Furthermore, we found that MeCP2 directly binds AFF4, the scaffold of the SEC, via the transcriptional repression domain. Finally, loss of MeCP2 in the mouse cortex caused reduced binding of AFF4 specifically on a subset of genes involved in the regulation of synaptic function, which also displayed the strongest decrease in RNA pol II binding in the genebody. Taken together, our study reveals a previously unrecognized mechanism through which MeCP2 regulates transcription, providing a new dimension to its regulatory role in gene expression.

MeCP2 and neurodevelopmental disorders

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

Emerging physiological and pathological roles of MeCP2 in non-neurological systems

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

MeCP2 links heterochromatin condensates and neurodevelopmental disease

MeCP2-Related Diseases and Animal Models

Research Progress of Rett Syndrome Causing Gene MECP2-The Structure, Function and Modulation of MECP2

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

SUMOylation of MeCP2 is essential for transcriptional repression and hippocampal synapse development.

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

Reciprocal regulation of autism-related genes MeCP2 and PTEN via microRNAs

MECP2-related disorders while gene-based therapies are on the horizon

Mecp2 Regulates The Timing Of Critical Period Plasticity That Shapes Functional Connectivity In Primary Visual Cortex

Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

The molecular pathology of rett syndrome